All patients see benefit in Mass Brigham's cornea stem cell therapy trial [Yahoo! Finance]
MeiraGTx Holdings plc - Ordinary Shares (MGTX)
Company Research
Source: Yahoo! Finance
Published in Nature Communications , results saw the study achieve success rates of 79% and 77% corneal repair with the cultivated autologous limbal epithelial cells (CALEC) graft, at the 12-month and 18-month marks respectively. All enrolled patients who received the CALEC graft saw an improvement in visual acuity. The single-site, first-in-human Phase I/II trial (NCT02592330) enrolled 14 patients who received the graft. Three patients have since received a second stem cell graft, with one going on to see a completely successful cornea restoration. CALECs are created by removing stem cells from a healthy eye with a biopsy, expanding them into a cellular tissue graft and surgically transplanting the graft into the eye. It does have limitations due to it being an autologous therapy, meaning that one eye must be healthy to provide viable stem cells for the graft. Mass Brigham hopes to develop an allogeneic therapy using cadaver donor eyes to make the approach accessible to patients
Show less
Read more
Impact Snapshot
Event Time:
MGTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGTX alerts
High impacting MeiraGTx Holdings plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MGTX
News
- MeiraGTx (NASDAQ:MGTX) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- MeiraGTx (NASDAQ:MGTX) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Graviton Bioscience to Present Selective ROCK2 Obesity Data at 8th Annual Evercore HealthCONx ConferencePR Newswire
- MeiraGTx (NASDAQ:MGTX) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.MarketBeat
- MeiraGTx Reports Third Quarter 2025 Financial and Operational ResultsGlobeNewswire
MGTX
Earnings
- 11/13/25 - Miss
MGTX
Sec Filings
- 12/23/25 - Form 4
- 11/24/25 - Form 4
- 11/13/25 - Form SCHEDULE
- MGTX's page on the SEC website